Evidence map›Paper›PMID 38912324›Full record

ArticleInternational journal of pharmaceutics: X2024

Research on the loading and release kinetics of the vincristine sulfate liposomes and its anti-breast cancer activity.

Zixu Liu, Yang Liu, Zixuan Wu, Boyuan Liu, Linxuan Zhao, Tian Yin, Yu Zhang, Haibing He, Jingxin Gou, Xing Tang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zixu LiuDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang 110116, China.
Yang LiuInnovative Research Center for Integrated Cancer Omics, Shengjing Hospital of China Medical University, Shenyang, China.
Zixuan WuDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang 110116, China.
Boyuan LiuDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang 110116, China.
Linxuan ZhaoDepartment of Pharmaceutics, College of Pharmacy Sciences, Jilin University, Changchun 130021, China.
Tian YinDepartment of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110116, China.
Yu ZhangDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang 110116, China.
Haibing HeDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang 110116, China.
Jingxin GouDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang 110116, China.
Xing TangDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang 110116, China.
Song GaoDepartment of Oncology, Shengjing Hospital of China Medical University, 39 Huaxiang Road, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vincristine (VCR), as a cytotoxic drug, is used clinically to treat acute lymphatic leukemia and breast cancer, and commonly used clinically as vincristine sulfate (VCRS). However, its clinical use is limited by unpredictable pharmacologic characteristics, a narrow therapeutic index, and neurotoxicity. The pH gradient method was used for active drug loading of VCRS, and the process route mainly includes the preparation of blank liposomes and drug-loaded liposomes. VCRS liposomes had suitable particle size, high encapsulation efficiency and good stability. The loading and release kinetics of VCRS liposomes were explored. By calculating the changes of encapsulation efficiency with time at different temperatures, it was confirmed that the drug-loading process of liposomes exhibited a first-order kinetic feature, and the activation energy required for the reaction was determined as 20.6 kcal/mol. The release behavior at different pH was also investigated, and it was demonstrated that the release behavior conformed to the first-order model, suggesting that the release mechanism of VCRS was simple transmembrane diffusion. VCRS liposomes also enhanced

Indexed as

Cancer treatmentDrug-loading kineticsLiposomesRelease kineticsVincristine sulfate

Identifiers

PMID38912324
PMCPMC11190724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.